Amikacin + ceftazidime therapy of experimental right-sided Pseudomonas aeruginosa endocarditis in rabbits

A. S. Bayer, K. Lam, D. Norman, K. S. Kim, J. O. Morrison

Research output: Contribution to journalArticlepeer-review

Abstract

We investigated the efficacy of a potent new antipseudomonal β-lactam agent, ceftazidime, in a model of right-sided Pseudomonas endocarditis in 72 rabbits. Animals received either: no therapy (controls), amikacin (15 mg/kg/day), ceftazidime (100 mg/kg/day) or amikacin + ceftazidime. Amikacin + ceftazidime was significantly more effective than single-drug regimens in terms of reduction of mortality (p<0.01), prevention of pulmonary infarction (p<0.05), reduction of mean vegetation titers of Pseudomonas aeruginosa (p<0.05 - p<0.0005), sterilization of vegetations (p<0.0005) and reduction in prevalence of bacteriologic relapse after therapy (p<0.005). There was no development of resistance in vivo to either amikacin or ceftazidime.

Original languageEnglish (US)
Pages (from-to)351-361
Number of pages11
JournalCHEMOTHERAPY
Volume31
Issue number5
DOIs
StatePublished - Jan 1 1985
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Amikacin + ceftazidime therapy of experimental right-sided Pseudomonas aeruginosa endocarditis in rabbits'. Together they form a unique fingerprint.

Cite this